• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Personalized Medicine Partnering Terms and Agreements Product Image

Personalized Medicine Partnering Terms and Agreements

  • Published: April 2014
  • Region: Global
  • 1880 Pages
  • CurrentPartnering

FEATURED COMPANIES

  • Abbott
  • Biogen Idec
  • Eli Lilly
  • Hospira
  • Mylan
  • Sanofi
  • MORE

Comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

The Personalized Medicine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter personalized medicine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are READ MORE >

TABLE OF CONTENTS

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in personalized medicine dealmaking

2.1. Introduction
2.2. Personalized medicine partnering over the years
2.2.1 Biomarker partnering over the years
2.2.2 Companion diagnostic partnering over the years
2.2.3 Pharmacogenomics partnering over the years
2.3. Big pharma personalized medicine dealmaking activity
2.3.1 Big pharma biomarker, companion diagnostic and pharmacogenomics dealmaking activity
2.4. Big pharma most active in personalized medicine
2.5. Personalized medicine partnering by deal type
2.5.1 Biomarker partnering by deal type
2.5.2 Companion diagnostic partnering by deal type
2.5.3 Pharmacogenomics partnering by deal type
2.6. Personalized medicine partnering by disease type
2.6.1 Biomarker partnering by disease type
2.6.2 Companion diagnostic partnering by disease type
2.6.3 Pharmacogenomics partnering by disease type
2.7 Average deal terms for personalized medicine
2.7.1 Personalized medicine headline values
2.7.2 Personalized medicine upfront payments
2.7.3 Personalized medicine milestone payments
2.7.4 Personalized medicine royalty rates
Chapter 3 – Leading biomarker deals

3.1. Introduction
3.2. Top biomarker deals by value
3.3. Top biomarker deals involving big pharma

Chapter 4 – Leading companion diagnostic deals

4.1. Introduction
4.2. Top companion diagnostic deals by value
4.3. Top companion diagnostic deals involving big pharma

Chapter 5 – Leading pharmacogenomics deals

5.1. Introduction
5.2. Top pharmacogenomics deals by value

Chapter 6 – Big pharma personalized medicine deals

6.1. Introduction
6.2. How to use big pharma personalized medicine partnering deals
6.3. Big pharma personalized medicine partnering company profiles
Abbott
Amgen
Astellas
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Eisai
Eli Lilly
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Kyowa Hakko Kirin
Merck & Co
Merck KGaA
Novartis
Novo Nordisk
Pfizer
Purdue
Roche
Sanofi
Servier
Takeda
Teva
UCB

Chapter 7 – Biomarker contracts dealmaking directory

7.1. Introduction
7.2. By Company A-Z
Abbott Laboratories
Adamis Pharmaceuticals
ADMA Biologics
Altair Nanotechnologies
Amarantus BioSciences
ARCA Biopharma
Arno Therapeutics
Arrayit
Arrayit Diagnostics
Avalon Pharmaceuticals
BG Medicine
Biogen Idec
Biotage
Caliper Life Sciences
Celera
Clinical Data
Columbia University
DeCODE Genetics
DiagnoCure
Enterome Bioscience
Galmed Pharmaceuticals
Gen-Probe
Genzyme
Genzyme Genetics
GlaxoSmithKline
Guided Therapeutics
Health Discovery
Intrexon
Inverness Medical Innovations
Invivis Pharmaceuticals
KineMed
Konica Minolta
Laboratory Corporation of America
Merck and Co
Novartis
Perugia University
Power3 Medical Products
Psynova Neurotech
Quest Diagnostics
Regulus Therapeutics
Response Genetics
Roche
Rules-Based Medicine
Sanofi
Skyline Diagnostics
The Regents of the University of California
Transgenomic
TrovaGene
University of Cambridge
University of Cincinnati
US Army
Wayne State University
Zora Biosciences
7.3. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Contract service
Development
Distribution
Equity purchase
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Supply
7.4. By therapy type
Cardiovascular
Central Nervous System
Genetic disorders
Metabolic
Musculoskeletal
Oncology
Respiratory

Chapter 8 – Companion diagnostic contracts dealmaking directory

8.1. Introduction
8.2. By Company A-Z
Achaogen
AmpliPhi Biosciences
ARK Diagnostics
Arno Therapeutics
BG Medicine
Biogen Idec
Celladon
Galmed Pharmaceuticals
Health Diagnostic Laboratory
Invivis Pharmaceuticals
Photocure ASA
Psynova Neurotech
Regulus Therapeutics
Roche
Rules-Based Medicine
Salix Pharmaceuticals
Verastem
Virovek
Whitehead Institute
Zora Biosciences
8.3. By deal type
Co-development
Collaborative R&D
Contract service
Development
Distribution
Licensing
Marketing
Option
Sub-license
8.4. By therapy area
Cardiovascular
Central Nervous System
Infectives
Metabolic
Oncology
Psychiatry

Chapter 9 – Pharmacogenomics contracts dealmaking directory

9.1. Introduction
9.2. By Company A-Z
America Stem Cell
Cephalon
Champions Oncology
Clinical Data
DARA BioSciences
GlaxoSmithKline
Response Genetics
Transgenomic
9.3. By deal type
Asset purchase
Collaborative R&D
Licensing
Material transfer
9.4. By therapy type
Hematology
Hospital care
Oncology

Chapter 10 – Personalized Medicine dealmaking directory by specific technology type

Personalized medicine
Pharmacogenomics
Biomarkers
Companion Diagnostics

Chapter 11 – Personalized medicine partnering resource center

11.1. Online personalized medicine partnering
11.2. Personalized medicine partnering events
11.3. Further reading on personalized medicine dealmaking

About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports

Table of figures

Figure 1: Personalized medicine partnering since 2009
Figure 2: Biomarker partnering since 2009
Figure 3: Companion diagnostic partnering since 2009
Figure 4: Pharmacogenomics partnering since 2009
Figure 5: Bigpharma – top 50 – personalized medicine deals 2009 to 2014
Figure 6: Big pharma personalized medicine deal frequency – 2009 to 2014
Figure 7: Big pharma – top 50 – biomarker, companion diagnostic and pharmacogenomics deals 2009 to 2014
Figure 8: Big pharma biomarker deal frequency – 2009 to 2014
Figure 9: Big pharma companion diagnostic deal frequency – 2009 to 2014
Figure 10: Big pharma pharmacogenomics deal frequency – 2009 to 2014
Figure 11: Most active big pharma in personalized medicine 2009-2014
Figure 12: Most active bigpharma in biomarkers 2009-2014
Figure 13: Most active bigpharma in companion diagnostic 2009-2014
Figure 14: Most active bigpharma pharmacogenomics dealmaking activity 2009-2014
Figure 15: Personalized medicine partnering by deal type since 2009
Figure 16: Biomarker partnering by deal type since 2009
Figure 17: Companion diagnositc partnering by deal type since 2009
Figure 18: Pharmacogenomics partnering by deal type since 2009
Figure 19: Personalized medicine partnering by disease type since 2009
Figure 20: Personalized medicine partnering by oncology target since 2009
Figure 21: Biomarker partnering by disease type since 2009
Figure 22: Biomarker partnering by oncology target since 2009
Figure 23: Companion diagnostic partnering by disease type since 2009
Figure 24: Companion diagnostic partnering by oncology target since 2009
Figure 25: Pharmacogenomics partnering by disease type since 2009
Figure 26: Pharmacogenomics partnering by oncology target since 2009
Figure 27: Personalized medicine deals with a headline value
Figure 28: Personalized medicine deals headline value distribution, US$m – 2009-2014: discovery
Figure 29: Personalized medicine deals headline value distribution, US$m – 2009-2014: preclinical
Figure 30: Personalized medicine deals headline value distribution, US$m – 2009-2014: phase I
Figure 31: Personalized medicine deals headline value distribution, US$m – 2009-2014: phase II
Figure 32: Personalized medicine deals headline value distribution, US$m – 2009-2014: phase III
Figure 33: Personalized medicine deals headline value distribution, US$m – 2009-2014: regulatory
Figure 34: Personalized medicine deals headline value distribution, US$m – 2009-2014: marketed stage
Figure 35: Summary median headline value by stage of development, 2009-2014
Figure 36: Personalized medicine deals with an upfront value
Figure 37: Personalized medicine deals upfront value distribution, US$m – 2009-2014: discovery
Figure 38: Personalized medicine deals upfront value distribution, US$m – 2009-2014: preclinical
Figure 39: Personalized medicine deals upfront value distribution, US$m – 2009-2014: phase I
Figure 40: Personalized medicine deals upfront value distribution, US$m – 2009-2014: phase II
Figure 41: Personalized medicine deals upfront value distribution, US$m – 2009-2014: phase III
Figure 42: Personalized medicine deals upfront value distribution, US$m – 2009-2014: regulatory
Figure 43: Personalized medicine deals upfront value distribution, US$m – 2009-2014: marketed
Figure 44: Summary median upfront value by stage of development, 2009-2014
Figure 45: Personalized medicine deals with a milestone value
Figure 46: Personalized medicine deals milestone value distribution, US$m – 2009-2014: discovery
Figure 47: Personalized medicine deals milestone value distribution, US$m – 2009-2014: preclinical
Figure 48: Personalized medicine deals milestone value distribution, US$m – 2009-2014: phase I
Figure 49: Personalized medicine deals milestone value distribution, US$m – 2009-2014: phase II
Figure 50: Personalized medicine deals milestone value distribution, US$m – 2009-2014: phase III
Figure 51: Personalized medicine deals milestone value distribution, US$m – 2009-2014: regulatory
Figure 52: Personalized medicine deals milestone value distribution, US$m – 2009-2014: marketed
Figure 53: Personalized medicine deals with a royalty rate value
Figure 54: Personalized medicine deals royalty rate value distribution, % – 2009-2014: discovery
Figure 55: Personalized medicine deals royalty rate value distribution, % – 2009-2014: preclinical
Figure 56: Personalized medicine deals royalty rate value distribution, % – 2009-2014: phase I
Figure 57: Personalized medicine deals royalty rate value distribution, % – 2009-2014: phase II
Figure 58: Personalized medicine deals royalty rate value distribution, % – 2009-2014: phase III
Figure 59: Personalized medicine deals royalty rate value distribution % – 2009-2014: regulatory
Figure 60: Personalized medicine deals royalty rate value distribution, % – 2009-2014: marketed stage
Figure 61: Summary median royalty rate value % by stage of development, 2009-2014
Figure 62: Top biomarker deals by value since 2009
Figure 63: Top biomarker deals signed by big pharma value since 2009
Figure 64: Top companion diagnostic deals by value since 2009
Figure 65: Top companion diagnostic deals signed by big pharma value since 2009
Figure 66: Top pharmacogenomics deals by value since 2009
Figure 67: Online partnering resources
Figure 68: Forthcoming partnering events

The Personalized Medicine Partnering Terms & Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

Benefits

Personalized Medicine Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of personalized medicine deal trends since 2007
Access to headline, upfront, milestone and royalty data
Analysis of the structure of personalized medicine agreements with numerous real life case studies
Comprehensive access to over 1500 actual personalized medicine contracts entered into by the world’s biopharma companies
Detailed access to actual personalized medicine contracts enter into by the leading fifty bigpharma companies
Insight into the terms included in a personalized medicine agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Abbott
Actavis
Allergan
Amgen
Astellas
AstraZeneca
Baxter
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo
Forest
Fresenius
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Mylan
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Ranbaxy
Roche
Sanofi
Servier
Shionogi
Shire
Stada
Takeda
Teva
UCB view
Valeant
Warner Chilcott

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos